PMID- 22641598
OWN - NLM
STAT- MEDLINE
DCOM- 20121009
LR  - 20151119
IS  - 1809-4570 (Electronic)
IS  - 0482-5004 (Linking)
VI  - 52
IP  - 3
DP  - 2012 May-Jun
TI  - Cutaneous leishmaniasis in a patient with ankylosing spondylitis using 
      adalimumab.
PG  - 447-52
LID - S0482-50042012000300014 [pii]
AB  - Leishmaniasis is an anthropozoonosis caused by species of Leishmania and can have 
      different clinical presentations, depending on the parasite-host relationship. 
      Tumor necrosis factor-alpha (TNF-alpha) is a cytokine essential to infection control, 
      especially against intracellular parasites such as Leishmania. Anti-TNF-alpha 
      strategies have had a marked impact on the treatment of rheumatic diseases, but 
      the clinical use of those antagonists has been accompanied by an increased report 
      of infections. We report the first case of cutaneous leishmaniasis in a patient 
      with ankylosing spondylitis treated with adalimumab and methotrexate in Brazil. 
      We believe that, in this case, there was no association between the anti-TNF-alpha 
      treatment and cutaneous leishmaniasis, because the disease was limited to only 
      one ulcer that healed completely after treatment. More studies, however, are 
      necessary to better understand the possible relationship between anti-TNF-alpha 
      agents and leishmaniasis.
FAU - Gomes, Kirla Wagner Poti
AU  - Gomes KW
AD  - Hospital Geral de Fortaleza. nunesb@hotmail.com
FAU - Benevides, Andre Nunes
AU  - Benevides AN
FAU - Vieira, Francisco Jose Fernandes
AU  - Vieira FJ
FAU - Burlamaqui, Maggy Poti de Morais
AU  - Burlamaqui MP
FAU - Vieira, Marcos de Almeida e Pontes
AU  - Vieira Mde A
FAU - Fontenelle, Lysiane Maria Adeodato Ramos
AU  - Fontenelle LM
LA  - eng
LA  - por
PT  - Case Reports
PT  - Journal Article
PL  - Brazil
TA  - Rev Bras Reumatol
JT  - Revista brasileira de reumatologia
JID - 0404256
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Antirheumatic Agents/*therapeutic use
MH  - Female
MH  - Humans
MH  - *Leishmaniasis, Cutaneous/etiology
MH  - Spondylitis, Ankylosing/*drug therapy
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
EDAT- 2012/05/30 06:00
MHDA- 2012/10/10 06:00
CRDT- 2012/05/30 06:00
PHST- 2011/02/20 00:00 [received]
PHST- 2011/03/05 00:00 [accepted]
PHST- 2012/05/30 06:00 [entrez]
PHST- 2012/05/30 06:00 [pubmed]
PHST- 2012/10/10 06:00 [medline]
AID - S0482-50042012000300014 [pii]
PST - ppublish
SO  - Rev Bras Reumatol. 2012 May-Jun;52(3):447-52.